Search

Displaying results 2211 - 2220 of 8412 in total
  1. Drug

    Washed Microbiota Transplantation

    go.drugbank.com/drugs/DB15745
    Investigational

    Washed microbiota preparation (WMT) involves a method wherein FMT is used, but the preparation undergoes microfiltration through an automatic purification system combined with repeated centrifugation and

  2. Drug

    Growth hormone-releasing peptide 1

    go.drugbank.com/drugs/DB19259
    Investigational

    investigation in clinical trial NCT00381602 (A Phase II, Randomized, Cross-over, Vehicle-controlled, Double-blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG

    Synonyms: Ala-his-3-(2-naphthalenyl)-d-ala-ala-trp-d-phe-lys-nh2, L-alanyl-l-histidyl-3-(2-naphthalenyl)-d-alanyl-l-alanyl-l-tryptophyl-d-phenylalanyl-l-lysinamide
  3. Drug

    Econazole

    go.drugbank.com/drugs/DB01127
    Approved

    A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.

    Mixtures: PM ExternalCategories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2E1 Inhibitors
  4. Indication

    Osteoporosis

    go.drugbank.com/conditions/DBCOND0015928
    Drugs: Abaloparatide · Alendronic acid · Boron · Calcium · Calcium carbonate · Calcium citrate +20 more
  5. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  6. Drug

    PF-4191834

    go.drugbank.com/drugs/DB11645
    Investigational

    PF-4191834 has been investigated for the basic science of Asthma.

  7. Drug

    CA-170

    go.drugbank.com/drugs/DB15772
    Investigational

    CA-170 is a selective, small molecule inhibitor of PD-L1.

  8. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.

  9. Drug

    Ceritinib

    go.drugbank.com/drugs/DB09063
    ApprovedInvestigational

    Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme. … The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    Altretamine

    go.drugbank.com/drugs/DB00488
    ApprovedWithdrawn

    An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.